Clinical Trial

A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to standard clinical care in Chinese patients with acute anterior ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (pPCI).
Protocol Amendment History 5 changes
critical Primary endpoint(s) modified 2026-07-14
minor Trial arms changed: 2 -> 3 2026-07-14
notable Primary completion moved earlier: 2027-06 -> 2027-04 2026-07-14
minor Completion pushed: 2027-06 -> 2027-10 2026-07-14
critical Recruitment opened 2026-05-20
Trial Details
NCT Number NCT07306182
Lead Sponsor Beijing Sungen Biomedical Technology Co., Ltd
Conditions Acute Anterior ST-Segment Elevation Myocardial Infarction
Enrollment 210 participants
Start Date 2026-03-09
Primary Completion 2027-04 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-13